Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)8.44
  • Today's Change0.24 / 2.93%
  • Shares traded17.82k
  • 1 Year change-13.52%
  • Beta0.8699
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2612761
Total Receivables, Net198.329.81
Total Inventory----4.00
Prepaid expenses5.750.920.70
Other current assets, total0.00----
Total current assets2863675
Property, plant & equipment, net0.881.590.09
Goodwill, net181833
Intangibles, net6.606.61(0.65)
Long term investments13122.96
Note receivable - long term------
Other long term assets0.00----
Total assets32776110
LIABILITIES
Accounts payable471519
Accrued expenses6.072.302.65
Notes payable/short-term debt000
Current portion long-term debt/capital leases3111--
Other current liabilities, total6.143.666.84
Total current liabilities913228
Total long term debt243253
Total debt554253
Deferred income tax------
Minority interest------
Other liabilities, total164.480.10
Total liabilities1316882
SHAREHOLDERS EQUITY
Common stock0.630.220.17
Additional paid-in capital478150108
Retained earnings (accumulated deficit)(283)(144)(79)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.11----
Total equity1967.1929
Total liabilities & shareholders' equity32776110
Total common shares outstanding632217
Treasury shares - common primary issue0.010.010.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.